Kathleen Moore to Treatment Outcome
This is a "connection" page, showing publications Kathleen Moore has written about Treatment Outcome.
Connection Strength
0.802
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388.
Score: 0.113
-
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
Score: 0.110
-
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
Score: 0.095
-
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 07; 3(4):284-9.
Score: 0.071
-
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int J Gynecol Cancer. 2014 Mar; 24(3):564-9.
Score: 0.070
-
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71.
Score: 0.046
-
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403.
Score: 0.045
-
Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007 Aug; 197(2):141.e1-6.
Score: 0.044
-
Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8.
Score: 0.044
-
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021 Feb; 8(2):e122-e134.
Score: 0.028
-
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.
Score: 0.026
-
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
Score: 0.023
-
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
Score: 0.022
-
Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52.
Score: 0.021
-
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
Score: 0.016
-
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J Gynecol Cancer. 2013 Jan; 23(1):98-104.
Score: 0.016
-
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010 Jan; 116(1):10-4.
Score: 0.013